[
  {
    "ts": null,
    "headline": "Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss",
    "summary": "Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.",
    "url": "https://finnhub.io/api/news?id=2575995bb7e5521d208d58956abae44b0eef22d63b35e8c0e9cdcc144f381340",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768333149,
      "headline": "Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss",
      "id": 138112877,
      "image": "https://image.cnbcfm.com/api/v1/image/108252045-3ED3-MM-C-BLOCK-SHORT-011326.jpg?v=1768349947&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.",
      "url": "https://finnhub.io/api/news?id=2575995bb7e5521d208d58956abae44b0eef22d63b35e8c0e9cdcc144f381340"
    }
  },
  {
    "ts": null,
    "headline": "Amgen CEO Bob Bradway goes one-on-one with Jim Cramer",
    "summary": "Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.",
    "url": "https://finnhub.io/api/news?id=f546a71f7db7e3007bbcd77b21787509ce35be0b4eefb565383ea8f5c6859659",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768333092,
      "headline": "Amgen CEO Bob Bradway goes one-on-one with Jim Cramer",
      "id": 138112878,
      "image": "https://image.cnbcfm.com/api/v1/image/108252044-3ED3-MM-C-BLOCK-011326.jpg?v=1768349909&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.",
      "url": "https://finnhub.io/api/news?id=f546a71f7db7e3007bbcd77b21787509ce35be0b4eefb565383ea8f5c6859659"
    }
  },
  {
    "ts": null,
    "headline": "Wednesday's big stock stories: What’s likely to move the market in the next trading session",
    "summary": "The S&P 500 dipped on Tuesday. The financials sector weighed down the broad market index as JPMorgan sold off after the bank issued its latest earnings report.",
    "url": "https://finnhub.io/api/news?id=c2dda5ea091add612e37d586480cdef6e691816f6a1046e68039e85eddec4274",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768332958,
      "headline": "Wednesday's big stock stories: What’s likely to move the market in the next trading session",
      "id": 138112692,
      "image": "https://image.cnbcfm.com/api/v1/image/108171463-1752497175307-gettyimages-2202903736-20250224_retail_135.jpeg?v=1768350739&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "The S&P 500 dipped on Tuesday. The financials sector weighed down the broad market index as JPMorgan sold off after the bank issued its latest earnings report. ",
      "url": "https://finnhub.io/api/news?id=c2dda5ea091add612e37d586480cdef6e691816f6a1046e68039e85eddec4274"
    }
  },
  {
    "ts": null,
    "headline": "Amgen CEO says weight loss drug can address 'patient persistence issue'",
    "summary": "Amgen CEO Bob Bradway discussed his company's weight loss drug in an interview with CNBC's Jim Cramer.",
    "url": "https://finnhub.io/api/news?id=5fc449f69ea3098126a9cd80f34326a19290fa4c6bd25fc9266328f767b93c9d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768329977,
      "headline": "Amgen CEO says weight loss drug can address 'patient persistence issue'",
      "id": 138112880,
      "image": "https://image.cnbcfm.com/api/v1/image/107390832-1711031881240-gettyimages-1244662987-porzycki-pharmace221110_npGy2.jpeg?v=1768348095&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Amgen CEO Bob Bradway discussed his company's weight loss drug in an interview with CNBC's Jim Cramer.",
      "url": "https://finnhub.io/api/news?id=5fc449f69ea3098126a9cd80f34326a19290fa4c6bd25fc9266328f767b93c9d"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=6a850bf418cb6207de7a0e9485f89d01aaf97e361952dc34c6a5facdbcc2063d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768312804,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 138086786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=6a850bf418cb6207de7a0e9485f89d01aaf97e361952dc34c6a5facdbcc2063d"
    }
  },
  {
    "ts": null,
    "headline": "RO ANNOUNCES RESEARCH COLLABORATION TO BETTER UNDERSTAND AND IMPROVE THE REAL-WORLD PATIENT EXPERIENCE WITH GLP-1S",
    "summary": "Ro, the leading direct-to-patient healthcare company, today announced a research collaboration with Amgen to study barriers to care and patients' treatment experience. Powered by data from Ro's nationwide platform, the research will evaluate the real-world challenges that patients and providers must navigate in order to access and deliver evidence-based obesity care.",
    "url": "https://finnhub.io/api/news?id=bca88669a055c3b70efcbc940de1a4943903e7a3db1319b9d26b4112089ec73f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768309200,
      "headline": "RO ANNOUNCES RESEARCH COLLABORATION TO BETTER UNDERSTAND AND IMPROVE THE REAL-WORLD PATIENT EXPERIENCE WITH GLP-1S",
      "id": 138083390,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Ro, the leading direct-to-patient healthcare company, today announced a research collaboration with Amgen to study barriers to care and patients' treatment experience. Powered by data from Ro's nationwide platform, the research will evaluate the real-world challenges that patients and providers must navigate in order to access and deliver evidence-based obesity care.",
      "url": "https://finnhub.io/api/news?id=bca88669a055c3b70efcbc940de1a4943903e7a3db1319b9d26b4112089ec73f"
    }
  },
  {
    "ts": null,
    "headline": "Stage Set For Moat Stocks After Strong 2025 Close",
    "summary": "Stage Set For Moat Stocks After Strong 2025 Close",
    "url": "https://finnhub.io/api/news?id=9a4faadb1d0ec60765098b83ac8f02b4dfb1d4ee52fad0abf5038e10198cd400",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768286520,
      "headline": "Stage Set For Moat Stocks After Strong 2025 Close",
      "id": 138082325,
      "image": "",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9a4faadb1d0ec60765098b83ac8f02b4dfb1d4ee52fad0abf5038e10198cd400"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock to Keep an Eye On and 2 We Ignore",
    "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 18.7% over the past six months while the S&P 500 was up 11.1%.",
    "url": "https://finnhub.io/api/news?id=e2210a8080a3e750b10d9a7379f019a1449dcbc126f54f5f5055c34c3cc65545",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768279033,
      "headline": "1 Healthcare Stock to Keep an Eye On and 2 We Ignore",
      "id": 138083391,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 18.7% over the past six months while the S&P 500 was up 11.1%.",
      "url": "https://finnhub.io/api/news?id=e2210a8080a3e750b10d9a7379f019a1449dcbc126f54f5f5055c34c3cc65545"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Calls 2026 a “Springboard Year” as CEO Flags Major Data, MariTide Phase 3 Push at JPM Event",
    "summary": "Amgen (NASDAQ:AMGN) Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a “springboard year,” driven in part by what he described as a significant amount of clinical data expected across the portfolio. Bradway also reviewed 2025 performance",
    "url": "https://finnhub.io/api/news?id=41dcd34781d8d6d800f794450f53a66dcabd450c4a695ab2250f5881eaeb31e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768266313,
      "headline": "Amgen Calls 2026 a “Springboard Year” as CEO Flags Major Data, MariTide Phase 3 Push at JPM Event",
      "id": 138083392,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a “springboard year,” driven in part by what he described as a significant amount of clinical data expected across the portfolio. Bradway also reviewed 2025 performance",
      "url": "https://finnhub.io/api/news?id=41dcd34781d8d6d800f794450f53a66dcabd450c4a695ab2250f5881eaeb31e6"
    }
  }
]